Last updated: February 23, 2026
What is the Drug Identified by NDC 46122-0535?
NDC 46122-0535 refers to Luspatercept-aamt (trade name: Reblozyl), a medication approved by the FDA in November 2019. It is indicated for adult patients with anemia related to β-thalassemia and myelodysplastic syndromes (MDS). The drug is administered via subcutaneous injection.
Current Market Position
Luspatercept targets a niche population of rare blood disorders, limiting the total addressable market compared to broader anemia treatments. The key value propositions include its ability to reduce transfusion dependence, which appeals to healthcare providers managing chronic anemia.
Market Size and Patient Population
U.S. Market Assessment (2023)
| Condition |
Estimated Patients (U.S.) |
Source |
| β-thalassemia |
3,000 – 4,000 |
National Institutes of Health (NIH) [1] |
| Myelodysplastic syndromes (MDS) |
60,000 – 80,000 |
American Cancer Society (ACS) [2] |
Market Penetration and Growth Drivers
- Increased diagnosis rates due to improved awareness.
- Expansion of approved indications, including use in higher-risk MDS.
- Packages with patient support programs to enhance adherence.
Competitive Landscape
- Main competitors include erythropoiesis-stimulating agents (ESAs) such as epoetin alfa.
- Other novel agents in late-stage development for the same indications include Rogosertib and Luspatercept’s emerging biosimilars.
Pricing Overview and Historical Data
Listing Price
- The wholesale acquisition cost (WAC) for Reblozyl in 2023 is approximately $2,500 per dose.
- Typical treatment involves a weekly or bi-weekly subcutaneous injection.
Cost Per Year
| Treatment Assumptions |
Cost ($) |
| Average of 2 doses/month for 12 months |
$60,000 (at $2,500/dose) |
| With dose adjustments, range varies |
$50,000 – $70,000 |
Insurance and Reimbursement
- Commercial insurers and Medicare Part D generally cover Reblozyl.
- Patient co-pays depend on insurance tier; rebates and discounts influence net prices.
Price Projections (2024-2028)
Market Dynamics Influencing Prices
- Patent Status: Patent expiry is anticipated around 2032; generic biosimilars could enter the market in late 2020s.
- Regulatory Changes: Possible healthcare policy shifts toward drug price regulation.
- Market Demand: Steady growth expected; however, price sensitivity may reduce premiums with biosimilar competition.
Price Trends
| Year |
Projected Average Price per Dose |
Rationale |
| 2024 |
$2,500 |
Stable, with typical inflation adjustments |
| 2025 |
$2,450 (~2% decrease) |
Biosimilar competition begins emerging |
| 2026 |
$2,400 |
Increased market penetration reduces premiums |
| 2027 |
$2,300 |
Biosimilars gaining approval; price competition intensifies |
| 2028 |
$2,200 |
Continued market pressure and patent protections |
Revenue Projections
Based on the above, annual revenues are projected as follows:
| Year |
Estimated Patients (U.S.) |
Revenue (millions USD) |
Assumptions |
| 2024 |
4,000 |
~$240 |
100% market penetration, stable pricing |
| 2025 |
4,200 |
~$252 |
Slight growth; price decline slightly offset by patient increase |
| 2026 |
4,500 |
~$270 |
Market expansion, health policy influences |
| 2027 |
4,800 |
~$276 |
Biosimilar entry depresses prices slightly |
| 2028 |
5,000 |
~$275 |
Stabilization post-biosimilar market entry |
Key Market Considerations
- Regulatory trends: Increasing acceptance of biosimilars is expected to reduce prices over time.
- Manufacturing innovations: Enhanced biosimilar production efficiencies could accelerate price declines.
- Clinical consolidation: Larger healthcare systems might negotiate better prices, influencing average market prices.
Key Takeaways
- NDC 46122-0535 (Reblozyl) faces a niche, growing market for anemia related to β-thalassemia and MDS.
- Current U.S. list prices are around $2,500 per dose, with annual treatment costs near $60,000.
- Price projections indicate a gradual decline of about 10% over five years due to biosimilar competition and market dynamics.
- Revenues are expected to show modest growth, contingent on market penetration and reimbursement landscape stability.
- Patent expiry around 2032 and biosimilar entry will significantly influence long-term pricing.
FAQs
1. What factors most influence Reblozyl’s price trajectory?
Patent status, biosimilar market entry, healthcare policy changes, and insurance reimbursement strategies.
2. How does Reblozyl compare with alternative therapies?
It offers a reduction in transfusion dependence, a significant benefit over traditional ESAs, but at a higher price point.
3. Are biosimilars likely to affect Reblozyl’s price soon?
Yes, biosimilar development is progressing, potentially impacting prices after FDA approval, anticipated late 2020s.
4. How does market growth in rare blood disorder treatment impact pricing?
Steady or increasing prevalence coupled with unmet needs supports stable or rising prices until biosimilar competition intensifies.
5. What are the risks to revenue projections?
Regulatory shifts, biosimilar interference, patent litigations, and market adoption rates.
References
- National Institutes of Health. (2022). Thalassemia. https://www.nhlbi.nih.gov/health-topics/thalassemia
- American Cancer Society. (2023). Myelodysplastic Syndromes. https://www.cancer.org/cancer/myelodysplastic-syndrome.html
